Neuroblastoma · 5 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Busulfan and Melphalan Variant #01 | — | R 5 951 | — | — | — | ~1 | ~R 5 951 PFS proxy · indirect | 1 |
GM-CSF, IL-2, Isotretinoin, Dinutuximab Variant not yet assigned - COG protocol Partial | — | R 4 715 | 28d | — | — | ~6 | ~R 28 288 indirect | — |
Isotretinoin monotherapy Variant #01 | — | R 2 045 | 28d | — | — | ~6 | ~R 12 272 indirect | — |
Isotretinoin and Dinutuximab beta Variant #01 Partial | — | R 2 045 | 35d | — | — | ~6 | ~R 12 272 indirect | — |
Observation Partial | — | — | — | ~10.3 mo | ~37.1 mo | — | — | 65 |
5 of 5 regimens shown